When three patients die after taking a cutting-edge drug, most companies hit the brakes. Not Sarepta Therapeutics. The ...

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% Friday, halting the momentum the stock generated just a day earlier after ...

U.S. stocks ended the week mostly higher, with the S&P 500 (+0.6%) and Nasdaq (+1.5%) setting new record highs, lifted by strong Q2 earnings and softer-than-expected inflation data. June retail sales ...

Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after ...

Massachusetts-based Sarepta Therapeutics, facing scrutiny from regulators, is reducing its global workforce by 36% in an ...

Stocks turned in a lackluster performance Friday as Wall Street took a breather at the end of the first week of ...

Second-quarter profit jumps 46% at Netflix, while a report says Union Pacific is in early-stage talks to buy smaller railroad ...

What Happened? A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with ...

What Happened? A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the ...

What Happened? A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the ...

What Happened? A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the ...